MedTrace Logo

Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures

NCT06590896 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-06-03

No results posted yet for this study

Summary

To evaluate the long-term safety and tolerability of cenobamate in Japanese epilepsy patients with partial seizures

Conditions

  • Epilepsies, Partial

Interventions

DRUG

Cenobamate

Cenobamate will be orally administered once daily.

Sponsors & Collaborators

  • Ono Pharmaceutical Co. Ltd

    lead INDUSTRY

Principal Investigators

  • Project Leader · Ono Pharmaceutical Co. Ltd

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-04
Primary Completion
2027-01-31
Completion
2027-01-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06590896 on ClinicalTrials.gov